Trial · NCT03976258
Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV
NCT03976258, Completed, MetroHealth Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV. Trials, record NCT03976258. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03976258
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV
- NCT number
- NCT03976258
- Status
- Completed
- Enrollment
- 190 participants, actual
- Lead sponsor
- MetroHealth Medical Center
- Conditions
- HIV Infection, Opioid-use Disorder, Cardiovascular Diseases
- Interventions
- buprenorphine/naloxone, Methadone, Naltrexone Injection, Heroin
- First posted
- 2019-06-05
- Last updated
- 2023-10-02
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in plasma soluble CD14 concentration | 48 weeks | soluble marker of monocyte activation |
| Primary | Change in Endopat measure of microvascular function | 48 weeks | Measure of endothelial function |
| Primary | Change in target to background ratio measured by fluorodeoxyglucose (FDG)-positron emission tomography (PET) | 48 weeks | Measure of vascular inflammation |
| Primary | Change in plasma Interferon Gamma-Induced Protein 10 concentration | 48 weeks | soluble marker of inflammation |
| Primary | Change in plasma intestinal fatty acid binding protein concentration | 48 weeks | soluble marker of gut integrity |
| Secondary | Change in total fat stores measured by Whole body Dual-energy X-ray absorptiometry | 48 weeks | Measurement of fat stores |
| Secondary | Change in aortofemoral pulse wave velocity | 48 weeks | Measure of arterial stiffness |
| Secondary | Change is waist to hip ratio | 48 weeks | Measurement of central obesity |
| Secondary | Change in body mass index | 48 weeks | Body measurement |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DA044576 | The impact of intravenous heroin use on immune activation in treated HIV | MCCOMSEY, GRACE A; HILEMAN, CORRILYNN OLESKY | CASE WESTERN RESERVE UNIVERSITY | NATIONAL INSTITUTE ON DRUG ABUSE | 2017 to 2021 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03976258
GET https://conductscience.org/api/trials/v1/NCT03976258/registered